Parabilis Medicines appoints Craig Tendler to board as independent Class II director

Parabilis Medicines, Inc.

Board expanded to nine; Craig Tendler, M.D., appointed Class II director on Aug 22, 2026, term to 2028.
Receives stock option for 20,294 shares at $39.36/share, vesting monthly over 3 years.
Annual retainer of $40,000 for board plus $7,500 for Science & Technology Committee service.
Tendler brings 30+ years oncology development incl. two decades at J&J; joins Science & Technology Committee.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.